Thyroid-stimulating hormone (TSH) is associated with 30-day mortality in hip fracture patients

  • PDF / 573,890 Bytes
  • 7 Pages / 595.276 x 790.866 pts Page_size
  • 97 Downloads / 188 Views

DOWNLOAD

REPORT


ORIGINAL ARTICLE

Thyroid‑stimulating hormone (TSH) is associated with 30‑day mortality in hip fracture patients Etienne Rapacki1   · Jes B. Lauritzen2,3   · Christian M. Madsen3,4 · Henrik L. Jørgensen1,3   · Debbie Norring‑Agerskov1,5,6  Received: 12 August 2019 / Accepted: 25 October 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019

Abstract Purpose  The aim of this study is to assess the possible association between thyroid-stimulating hormone (TSH) and mortality in hip fracture patients. Patients and methods  The study is based on a hip fracture database from Bispebjerg University Hospital (Copenhagen, Denmark). This database includes all hip fracture patients (ICD-10 codes DS720 (femoral neck), DS721 (pertrochanteric), and DS722 (subtrochanteric)) admitted to Bispebjerg Hospital from 1996 to 2012. From this database, we identified all surgically treated hip fracture patients aged > 60 years with available plasma TSH-measurements at admission. Results  Of the 914 included patients (24% men and 76% women), 10.5% died within 30 days. At inclusion, 161 (17.6%) of the patients were hyperthyroid (TSH  4.8 mIU/L), while 695 (76.0%) were euthyroid (0.65